ADCs provide great efficacy in BLIS and LAR subtypes
SOLID TUMORS, BREAST CANCER
Considering the poor outcomes in BLIS and LAR subtype patients, we then tried to explore new treatment strategies for these patients. ADCs have shown strong antitumor activity in solid tumors, especially breast cancer.